Frequently Asked Questions
The market is segmented based on , By Diseases (Addison’s Disease, Gigantism, Goiter, Cushing’s Syndrome, Polycystic Ovary Syndrome (PCOS), Diabetes, Acromegaly, and Others), Drug Class (Estrogen, Testosterone, and Progesterone Replacement Therapy), Route of Administration (Oral and Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2031.
.
The Global Endocrine Disorders Market size was valued at USD 11.86 USD Billion in 2023.
The Global Endocrine Disorders Market is projected to grow at a CAGR of 7.4% during the forecast period of 2024 to 2031.
The major players operating in the market include Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (U.S.), Johnson & Johnson Services, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lilly and Company (U.S.), Merck & Co. Inc. (U.S.), Aurobindo Pharma (India), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Ascendis Pharma A/S (Denmark), and Bio-Rad Laboratories, Inc. (U.S.).
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
